Evaxion Biotech As Stock Revenue
| EVAX Stock | USD 1.66 0.09 5.73% |
Evaxion Biotech AS fundamentals help investors to digest information that contributes to Evaxion Biotech's financial success or failures. It also enables traders to predict the movement of Evaxion Stock. The fundamental analysis module provides a way to measure Evaxion Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Evaxion Biotech stock.
| Last Reported | Projected for Next Year | ||
| Total Revenue | 73 K | 76.7 K |
Evaxion | Revenue |
Evaxion Biotech AS Company Revenue Analysis
Evaxion Biotech's Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current Evaxion Biotech Revenue | 73 K |
Most of Evaxion Biotech's fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Evaxion Biotech AS is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Historical and Projected quarterly revenue of Evaxion
Projected quarterly revenue analysis of Evaxion Biotech AS provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of Evaxion Biotech match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in Evaxion Biotech's stock price.
Evaxion Revenue Driver Correlations
Understanding the fundamental principles of building solid financial models for Evaxion Biotech is extremely important. It helps to project a fair market value of Evaxion Stock properly, considering its historical fundamentals such as Revenue. Since Evaxion Biotech's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Evaxion Biotech's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Evaxion Biotech's interrelated accounts and indicators.
Click cells to compare fundamentals
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Based on the latest financial disclosure, Evaxion Biotech AS reported 73 K of revenue. This is 100.0% lower than that of the Biotechnology sector and 99.99% lower than that of the Health Care industry. The revenue for all United States stocks is 100.0% higher than that of the company.
Evaxion Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Evaxion Biotech's direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Evaxion Biotech could also be used in its relative valuation, which is a method of valuing Evaxion Biotech by comparing valuation metrics of similar companies.Evaxion Biotech is currently under evaluation in revenue category among its peers.
Evaxion Biotech Institutional Holders
Institutional Holdings refers to the ownership stake in Evaxion Biotech that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Evaxion Biotech's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Evaxion Biotech's value.| Shares | Armistice Capital, Llc | 2024-09-30 | 483 K | Invst Llc | 2024-06-30 | 54 K | Citadel Advisors Llc | 2024-09-30 | 14.8 K | Beacon Capital Management, Llc | 2024-09-30 | 4.9 K | Jpmorgan Chase & Co | 2024-06-30 | 2.2 K | Rhumbline Advisers | 2024-06-30 | 290 | Southstate Corp | 2024-09-30 | 4.0 | Tower Research Capital Llc | 2024-06-30 | 0.0 |
Evaxion Fundamentals
| Return On Equity | -8.03 | ||||
| Return On Asset | -0.69 | ||||
| Operating Margin | (0.57) % | ||||
| Current Valuation | 12.23 M | ||||
| Shares Outstanding | 5.58 M | ||||
| Shares Owned By Insiders | 25.20 % | ||||
| Shares Owned By Institutions | 8.16 % | ||||
| Number Of Shares Shorted | 36.02 K | ||||
| Price To Book | 131.59 X | ||||
| Price To Sales | 2.96 X | ||||
| Revenue | 73 K | ||||
| EBITDA | (21.4 M) | ||||
| Net Income | (22.12 M) | ||||
| Cash And Equivalents | 25.25 M | ||||
| Cash Per Share | 1.06 X | ||||
| Total Debt | 10.87 M | ||||
| Debt To Equity | 0.48 % | ||||
| Current Ratio | 6.47 X | ||||
| Book Value Per Share | 0.01 X | ||||
| Cash Flow From Operations | (17.69 M) | ||||
| Short Ratio | 2.07 X | ||||
| Earnings Per Share | (2.80) X | ||||
| Target Price | 10.85 | ||||
| Number Of Employees | 49 | ||||
| Beta | -0.23 | ||||
| Market Capitalization | 13.28 M | ||||
| Total Asset | 12.89 M | ||||
| Retained Earnings | (107.97 M) | ||||
| Working Capital | 1.27 M | ||||
| Net Asset | 12.89 M |
About Evaxion Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Evaxion Biotech AS's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Evaxion Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Evaxion Biotech AS based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Evaxion Stock Analysis
When running Evaxion Biotech's price analysis, check to measure Evaxion Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Evaxion Biotech is operating at the current time. Most of Evaxion Biotech's value examination focuses on studying past and present price action to predict the probability of Evaxion Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Evaxion Biotech's price. Additionally, you may evaluate how the addition of Evaxion Biotech to your portfolios can decrease your overall portfolio volatility.